David Baker’s Technology Transfer and Advisory Roles

Updated April 2024

Founder/Co-Founder/Scientific Co-Founder Roles:

CompanyFoundedCompany Status
1Prospect Genomics1999Acquired in 2001 by Eli Lilly/Structural GenomiX.
2Bio Architecture Lab2008Closed, having licensed their technology to Statoil.
3Arzeda2009Active
4Pregenen2011Acquired in 2014 by Bluebird Bio.
5Cyrus Biotech2014*Active
6PvP Biologics2016*Acquired in 2020 by Takeda.
7Virvio2017Closed
8Icosavax2018*Acquired in 2024 by AstraZeneca.
9A-Alpha Bio2018*Active
10Neoleukin Therapeutics2018*Merged in 2023 with Neurogene.
11Sana Biotechnology2019Active
12Lyell Immunotherapeutics2019Active
13Mopac Biologics2020*Active
14Monod Bio2021*Active
15Brahma2021Active
16Charm2021Active
17Axxis2022*Active
18Lila2022*Active
19Vilya2023*Active
20Archon Biosciences2023*Active
21Xaira Therapeutics2024Active
* Emerged from the Institute for Protein Design Translational Investigator Program.

Advisor (Non-Founder) roles:

CompanyFoundedCompany Status
Cue Biopharma2014Active
Xaira Therapeutics2024Active

Rosetta Licensing:

Initially developed in the Baker Lab, Rosetta is a software package for biomolecular modeling, docking, and design. Rosetta has been licensed to numerous non-profit and for-profit organizations. Rosetta licensing is managed by UW CoMotion. Royalty proceeds are managed by the RosettaCommons.